Gainers

• PACS Group (NYSE:PACS) stock rose 17.6% to $37.5 during Tuesday's pre-market session. The company's market cap stands at $5.0 billion. As per the press release, Q1 earnings came out yesterday.
• Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 16.31% to $5.99. The company's market cap stands at $184.0 million.
• Macrogenics (NASDAQ:MGNX) stock increased by 16.27% to $3.43. The market value of their outstanding shares is at $187.4 million.
• USBC (AMEX:USBC) stock increased by 12.69% to $0.57. The market value of their outstanding shares is at $197.1 million.
• Phio Pharmaceuticals (NASDAQ:PHIO) shares rose 10.18% to $1.19. The market value of their outstanding shares is at $12.5 million. As per the press release, Q1 earnings came out 3 days ago.
• Dyadic International (NASDAQ:DYAI) stock rose 9.08% to $0.79. The company's market cap stands at $26.3 million.

Losers

• WORK Medical Tech Gr (NASDAQ:WOK) shares decreased by 45.7% to $2.13 during Tuesday's pre-market session.
• CEL-SCI (AMEX:CVM) stock decreased by 26.25% to $1.04. The company's market cap stands at $11.9 million.
• Pomdoctor (NASDAQ:POM) stock decreased by 22.69% to $0.11. The market value of their outstanding shares is at $17.6 million.
• China Pharma Holding (AMEX:CPHI) shares decreased by 21.78% to $0.42. The company's market cap stands at $2.6 million.
• Organigram Global (NASDAQ:OGI) shares fell 16.02% to $1.1. The market value of their outstanding shares is at $184.2 million. As per the news, the Q2 earnings report came out today.
• Ensysce Biosciences (NASDAQ:ENSC) shares decreased by 14.88% to $0.33. The market value of their outstanding shares is at $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.